Randomized phase II study of lapatinib plus vinorelbine versus vinorelbine in patients with HER2 positive metastatic breast cancer progressed after lapatinib and trastuzumab treatment

被引：1
|
作者：
Sim, S. H.
Park, I. H.
Jung, K. H.
Kim, S-B
Ahn, J-H
Lee, K-H
Im, S-A
Im, Y-H
Park, Y. H.
Sohn, J. H.
Kim, Y. J.
Lee, S.
Kim, H-J
Chae, Y. S.
Park, K-H
Nam, B-H
Lee, K. S.
Ro, J.
机构：
[1] Natl Canc Ctr, Goyang, South Korea
[2] Seoul Natl Univ Hosp, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[4] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[6] Korea Univ, Seoul, South Korea
[7] Natl Canc Ctr, Res Inst & Hosp, Goyang, South Korea
[8] Seoul Natl Univ, Bundang Hosp, Bundang, South Korea
[9] Chung Ang Univ, Coll Med, Seoul, South Korea
[10] Dong A Univ, Coll Med, Busan, South Korea
[11] Kyungpook Natl Univ, Coll Med, Daegu, South Korea
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P6-17-23
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-17-23
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Randomized study of pazopanib plus lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer
    Slamon, D.
    Gomez, H. L.
    Kabbinavar, F. F.
    Amit, O.
    Richie, M.
    Pandite, L.
    Goodman, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] LAPATINIB IN HER2 POSITIVE METASTATIC CARCINOMA BREAST
    Behera, M. K.
    Sharma, A.
    Shukla, P.
    Julka, P. K.
    Rath, G. K.
    ANNALS OF ONCOLOGY, 2012, 23 : 50 - 50
  • [43] A Systematic Review and Meta-analysis of the Combination of Vinorelbine and Lapatinib in Patients With Her2-positive Metastatic Breast Cancer
    Stravodimou, Athina
    Voutsadakis, Ioannis A.
    ANTICANCER RESEARCH, 2019, 39 (07) : 3295 - 3301
  • [44] A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for HER2 overexpressing metastatic breast cancer (MBC).
    Papadimitriou, Christos A.
    Sarosiek, Tomasz
    Pikiel, Joanna
    Karaszewska, Boguslawa
    Salat, Christoph
    Caglevic, Christian
    Potemski, Piotr
    Brain, Etienne
    Briggs, Kathryn Jane
    DeSilvio, Michelle
    Marini, Luca
    Janni, Wolfgang
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] Rechallenge of trastuzumab-based therapy in HER2-positive breast cancer patients who progressed after lapatinib plus capecitabine
    Khanmammadov, Nijat
    Dogan, Izzet
    Khishigsuren, Bayarmaa
    Azizy, Abdulmunir
    Saip, Pinar
    Aydiner, Adnan
    MEDICINE, 2025, 104 (06)
  • [46] A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer
    Janni, Wolfgang
    Sarosiek, Tomasz
    Karaszewska, Boguslawa
    Pikiel, Joanna
    Staroslawska, Elzbieta
    Potemski, Piotr
    Salat, Christoph
    Brain, Etienne
    Caglevic, Christian
    Briggs, Kathryn
    DeSilvio, Michelle
    Marini, Luca
    Papadimitriou, Christos
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 143 (03) : 493 - 505
  • [47] A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer
    Wolfgang Janni
    Tomasz Sarosiek
    Boguslawa Karaszewska
    Joanna Pikiel
    Elzbieta Staroslawska
    Piotr Potemski
    Christoph Salat
    Etienne Brain
    Christian Caglevic
    Kathryn Briggs
    Michelle DeSilvio
    Luca Marini
    Christos Papadimitriou
    Breast Cancer Research and Treatment, 2014, 143 : 493 - 505
  • [48] GEP01: A phase I pharmacokinetic study of lapatinib and iv vinorelbine in the treatment of HER2-positive locally advanced or metastatic breast cancer
    Rezai, Keyvan
    Isambert, Nicolas
    Brain, Etienne
    Dalenc, Florence
    Urien, Salk
    Dieras, Veronique
    Vanlemmens, Laurence
    Jimenez, Marta
    Roche, Henri
    Tresca, Patricia
    Fumoleau, Pierre
    Lokiec, Francois
    CANCER RESEARCH, 2011, 71
  • [49] A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study)
    Gomez, Henry L.
    Neciosup, Silvia
    Tosello, Celia
    Mano, Max
    Bines, Jose
    Ismael, Gustavo
    Santi, Patricia X.
    Pinczowski, Helio
    Neron, Yeni
    Fanelli, Marcello
    Fein, Luis
    Sampaio, Carlos
    Lerzo, Guillermo
    Capo, Adolfo
    Zarba, Juan J.
    Blajman, Cesar
    Varela, Mirta S.
    Martinez-Mesa, Jeovany
    Werutsky, Gustavo
    Barrios, Carlos H.
    CLINICAL BREAST CANCER, 2016, 16 (01) : 38 - 44
  • [50] Trastuzumab-Emtansine versus Capecitabine plus Lapatinib in Patients with previously treated HER2-positive metastatic Breast Cancer
    Ruckhaeberle, Eugen
    ONKOLOGE, 2017, 23 (11): : 940 - 942
12345